<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02276391</url>
  </required_header>
  <id_info>
    <org_study_id>502.571</org_study_id>
    <nct_id>NCT02276391</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Telmisartan as Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets in Healthy Male Volunteers</brief_title>
  <official_title>Bioequivalence of Telmisartan Administrated in Two Different Ways: Either in Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets (an Open-label, Randomised, Single-dose, Four-period Replicated Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To establish bioequivalence of telmisartan orally administrated in two different ways: either
      with a telmisartan 80 mg/hydrochlorothiazide (HCTZ) 12.5 mg fixed-dose combination tablet or
      with two telmisartan 40 mg tablets
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to the maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz (terminal rate constant of the analyte in plasma)</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (terminal half-life of the analyte in plasma)</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo (mean residence time of the analyte in the body after po administration)</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant findings in physical examination</measure>
    <time_frame>Up to 72 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant findings in vital signs</measure>
    <time_frame>Up to 72 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant findings in 12-lead ECG (electrocardiogram)</measure>
    <time_frame>Up to 72 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant findings in clinical laboratory parameters</measure>
    <time_frame>Up to 72 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 72 hours after last drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Telmisartan/HCTZ fixed-dose combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan/HCTZ combination</intervention_name>
    <arm_group_label>Telmisartan/HCTZ fixed-dose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <arm_group_label>Telmisartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy Japanese males according to the following criteria:

          1. Based upon a complete medical history, including the physical examination, vital signs
             (blood pressure (BP), pulse rate (PR), body temperature), 12-lead ECG
             (electrocardiogram), clinical laboratory tests

          2. Age ≥20 and Age ≤35 years

          3. Body weight ≥50 kg

          4. Body Mass Index (BMI) ≥18.0 and BMI ≤25.0 kg/m2

          5. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and the local legislation.

        Exclusion Criteria:

          1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          2. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          3. Chronic or relevant acute infections

          4. Any clinical relevant findings of the laboratory test deviating from normal

          5. Positive result for either hepatitis B surface (HBs) antigen, anti hepatitis C virus
             (HCV) antibodies, syphilitic test or human immunodeficiency virus (HIV) test

          6. History of surgery of gastrointestinal tract (except appendectomy)

          7. History of relevant orthostatic hypotension, fainting spells or blackouts

          8. Known hypersensitivity to any component of the formulation (telmisartan and
             hydrochlorothiazide), or to any other angiotensin II receptor blocker (ARBs), any
             other thiazides, or thiazide derivatives (e.c. sulfonamide derivatives like a
             chlorthalidone)

          9. History of hepatic dysfunction (e.g. biliary cirrhosis, cholestasis)

         10. History of serious renal dysfunction

         11. History of bilateral renal artery stenosis or renal artery stenosis in a solitary
             kidney

         12. History of cerebrovascular disorder

         13. History of hyperkalemia

         14. History of impaired glucose tolerance

         15. History of hypokalemia

         16. History of hyperuricemia

         17. Salt restriction therapy

         18. Intake of drugs with a long half-life (≥24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

         19. Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 7 days prior to administration or
             during the trial

         20. Participation in another trial with an investigational drug within 4 months or 6
             half-lives of the investigational drug prior to administration

         21. Smoker (≥20 cigarettes /day))

         22. Alcohol abuse (60 g or more ethanol/day: ex. 3 middle-sized bottles of beer, 3 gous
             (equivalent to 540 mL) of sake)

         23. Drug abuse

         24. Blood donation (more than 100 mL within 4 weeks prior to administration or during the
             trial)

         25. Excessive physical activities (within 1 week prior to administration or during the
             trial)

         26. Intake of alcohol within 2 days prior to administration

         27. Inability to comply with dietary regimen of study centre

         28. Inability to refrain from smoking on trial days

         29. Subjects judged to be inappropriate by the investigator or the sub-investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2014</study_first_submitted>
  <study_first_submitted_qc>October 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2014</study_first_posted>
  <last_update_submitted>October 27, 2014</last_update_submitted>
  <last_update_submitted_qc>October 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

